Infectious causes of cancer

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

Tuesday, January 19, 2021 - 1:30pm

PHALCON-HP is a randomized, multicenter, Phase 3 trial that has enrolled over 1,000 patients with H. pylori infection.

Key Points: 
  • PHALCON-HP is a randomized, multicenter, Phase 3 trial that has enrolled over 1,000 patients with H. pylori infection.
  • The completion of patient enrollment in the PHALCON-HP trial marks another significant milestone for Phathom and for the millions of people with H. pylori infection.
  • The second trial, PHALCON-EE, is a randomized, double-blind, two-phase, multicenter trial evaluating vonoprazan in the treatment of erosive esophagitis (EE).
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

Tuesday, January 19, 2021 - 12:00pm

The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.

Key Points: 
  • The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.
  • VP-102, our lead candidate, continues to demonstrate positive results as we advance development of the program in molluscum, external genital warts and common warts, three of the largest unmet needs in medical dermatology.
  • Data were also presented from Verricas Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW).
  • Verricas late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology.

Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Friday, January 15, 2021 - 9:10pm

Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).

Key Points: 
  • Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM).
  • Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
  • Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects.
  • Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.

Hepatocellular Carcinoma Epidemiology Forecast 2019-2020 & 2029: Understand Magnitude of HCC By Stage at Diagnosis, BCLC Stage, Child Pugh Stage, Risk Factors and Biomarkers

Thursday, January 14, 2021 - 7:30pm

Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver.

Key Points: 
  • Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver.
  • HCC is classified by various staging systems such as the Barcelona Clinic Liver Cancer (BCLC) stage and Child Pugh stages.
  • The diagnosed incident cases of HCC are further segmented by sex and age (18 years and older), BCLC Stage (stage A, stage B, stage C, and stage D), Child Pugh stage (Child Pugh stage A, Child Pugh stage B, and Child Pugh stage C), HCC risk factors (HBV, HCV, non-alcoholic steatohepatitis [NASH] or non-alcoholic fatty liver disease [NAFLD], and alcohol use), cirrhotic and non-cirrhotic HCC, and biomarkers (Alpha-fetoprotein [AFP], >400ng/mL).
  • Understand magnitude of HCC by stage at diagnosis, BCLC stage, Child Pugh stage, risk factors and biomarkers.

Pregna Launches CryoPop – a Carbon Dioxide (CO2) Based Innovative Cryotherapy Device to Fight Cervical Cancer

Thursday, January 14, 2021 - 4:00pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210114005049/en/
    The ingenious device was developed by Jhpiego with an objective of making treatment of cervical pre-cancerous lesions accessible to all.
  • The good news is that thanks to advancements in screening and diagnosis, cervical cancer is not only preventable, but also one of the most successfully treatable forms of cancer."
  • Cryotherapy is one of the most effective methods to treat cervical lesions, yet the infrastructure required in traditional equipments has hampered its large scale adoption.
  • January is observed as Cervical Cancer Awareness month , intended to raise awareness of cervical cancer and to educate about its cause, prevention, diagnosis, treatment, survivorship and cure.

Day Three of Bionano’s Next-Generation Cytogenomics Symposium: Saphyr Provides Complete Structural Variation Analysis in Solid Tumors, Enables Discovery of Novel Diagnostic Markers and Drug Targets

Thursday, January 14, 2021 - 1:00pm

He concluded that Saphyr is a powerful tool to identify and characterize viral integration in tumors and that it can detect the genome instability associated with HPV integration.

Key Points: 
  • He concluded that Saphyr is a powerful tool to identify and characterize viral integration in tumors and that it can detect the genome instability associated with HPV integration.
  • In addition to the higher performance, Saphyr has reduced hands-on time, faster turn-around time, and is cost effective compared to this current combination of methods.
  • He believes that tests developed on Saphyr may help in making a more accurate prognosis and could measure therapy response.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

New Research in JNCCN Highlights Dangerous Disparities for Life-Saving Cancer Screening

Wednesday, January 13, 2021 - 1:35pm

"These findings show we need more measures to eliminate socioeconomic-related health disparities in our communities, even where healthcare is publicly funded.

Key Points: 
  • "These findings show we need more measures to eliminate socioeconomic-related health disparities in our communities, even where healthcare is publicly funded.
  • Dr. Abdel-Rahman looked at self-reported data for 99,820 people eligible for colorectal cancer screening, 59,724 people eligible for breast cancer screening, and 46,767 in the cervical cancer screening cohort, based on Canadian guidelines from 2007 through 2016.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.
  • 1Hall IJ, Tangka FK, Sabatino SA, Thompson TD, Graubard BI, Breen N. Patterns and Trends in Cancer Screening in the United States.

New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®

Tuesday, January 12, 2021 - 7:45pm

These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population.

Key Points: 
  • These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population.
  • Study is among the first to evaluate the use of a colorectal cancer screening method in patients between ages of 45-49.
  • Cologuard is a U.S. Food & Drug Administration (FDA)-approved, non-invasive stool DNA test for colorectal cancer for average-risk people.
  • In September 2019, the FDA approved Cologuard for average-risk individuals beginning at age 45, expanding the Cologuard label to include this critical younger adult population.

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

Tuesday, January 12, 2021 - 1:00pm

We are enthusiastic about this collaboration, said Phil Pang, MD, PhD, Chief Medical Officer of Vir Biotechnology.

Key Points: 
  • We are enthusiastic about this collaboration, said Phil Pang, MD, PhD, Chief Medical Officer of Vir Biotechnology.
  • We believe that this collaboration with Gilead adds a novel and significant new combination to our efforts to find a cure for HBV.
  • VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
  • Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.

NEC Releases 'WISE VISION Endoscopy' in Europe and Japan

Tuesday, January 12, 2021 - 1:56am

TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.

Key Points: 
  • TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.
  • This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures.
  • Colorectal cancer is the most common cancer in Japan(1), and the second most common in Europe(2).
  • NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue.